Assembly Biosciences, Inc. (NASDAQ:ASMB) Expected to Announce Earnings of -$0.49 Per Share

Wall Street analysts expect that Assembly Biosciences, Inc. (NASDAQ:ASMBGet Rating) will announce earnings of ($0.49) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Assembly Biosciences’ earnings. The lowest EPS estimate is ($0.56) and the highest is ($0.35). Assembly Biosciences posted earnings per share of ($0.69) during the same quarter last year, which would indicate a positive year over year growth rate of 29%. The business is scheduled to report its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that Assembly Biosciences will report full-year earnings of ($2.00) per share for the current financial year, with EPS estimates ranging from ($2.31) to ($1.42). For the next financial year, analysts expect that the firm will post earnings of ($1.61) per share, with EPS estimates ranging from ($1.76) to ($1.49). Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Assembly Biosciences.

Assembly Biosciences (NASDAQ:ASMBGet Rating) last released its quarterly earnings data on Thursday, March 10th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.09.

A number of equities research analysts have recently issued reports on the stock. Truist Financial reduced their price target on shares of Assembly Biosciences from $15.00 to $12.00 and set a “buy” rating for the company in a research report on Friday, April 1st. Zacks Investment Research downgraded Assembly Biosciences from a “buy” rating to a “hold” rating in a research report on Tuesday, January 4th. Mizuho initiated coverage on Assembly Biosciences in a research report on Tuesday, March 22nd. They set a “buy” rating and a $14.00 price objective for the company. Finally, StockNews.com initiated coverage on Assembly Biosciences in a research report on Thursday, March 31st. They set a “sell” rating for the company. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $7.02.

Institutional investors and hedge funds have recently modified their holdings of the business. Royal Bank of Canada raised its holdings in Assembly Biosciences by 185.4% in the 2nd quarter. Royal Bank of Canada now owns 10,319 shares of the biopharmaceutical company’s stock valued at $40,000 after acquiring an additional 6,703 shares during the last quarter. Squarepoint Ops LLC purchased a new stake in shares of Assembly Biosciences during the 4th quarter valued at $31,000. Virtu Financial LLC purchased a new stake in shares of Assembly Biosciences during the 4th quarter valued at $83,000. Cubist Systematic Strategies LLC grew its stake in shares of Assembly Biosciences by 89.1% during the 4th quarter. Cubist Systematic Strategies LLC now owns 35,654 shares of the biopharmaceutical company’s stock valued at $83,000 after buying an additional 16,800 shares during the period. Finally, Assenagon Asset Management S.A. purchased a new stake in shares of Assembly Biosciences during the 1st quarter valued at $93,000. Institutional investors own 52.45% of the company’s stock.

Shares of NASDAQ ASMB traded down $0.10 during mid-day trading on Friday, reaching $1.76. The company’s stock had a trading volume of 160,754 shares, compared to its average volume of 362,396. The stock has a fifty day moving average of $1.87 and a two-hundred day moving average of $2.17. Assembly Biosciences has a 52 week low of $1.40 and a 52 week high of $4.69.

Assembly Biosciences Company Profile (Get Rating)

Assembly Biosciences, Inc, a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection.

Read More

Get a free copy of the Zacks research report on Assembly Biosciences (ASMB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Assembly Biosciences (NASDAQ:ASMB)

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.